DiagMMR is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers.

While current Lynch syndrome diagnosis relies heavily on tumor studies, the quantitative DiagMMR method allows carrier diagnosis based on a minimally invasive tissue sample before the person has developed any cancer, without the knowledge and details of an inherited mutation.

The inherent challenges to variant interpretation in genetic testing can be avoided and the conclusive and actionable results removes the burden of uncertainty from both the patients and the treating medical professionals.

LS CancerDiag Ltd is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.

Eon uses the most advanced form of AI to create layered Computational Linguistics (CL) data science models. CL understands text and the linguistic structure of English, similar to how the human brain reads. EPM eliminates the noise by extracting clinically relevant information from radiology reports, saves FTE time, and improves patient outcomes.

EPM is the first and only solution to identify incidental pulmonary nodules on Magnetic Resonance (MR), X-Ray, and Computed Tomography (CT) reports. This allows facilities to capture approximately 25% more incidental pulmonary nodules.

Eon is a digital health company that has created the industry's first Intelligent Care platform. Our advanced AI integrates with your EHR to identify incidental findings with 98% accuracy. From there, our technology risk-stratifies patients, creates custom care plans, and automates patient/provider outreach to increase adherence and outcomes.

The company now works with more than 1,000 hospitals, and has impacted more than 1.5 million patients.

• Robust computational linguistics models
• Care management support to offload nodule management to Eon teams
• Accuracy of nodule identification, and automation of next steps

• 1,000+ hospital and radiology center partners
• 414 million radiology scans analyzed since 2021
• 15.7 million abnormalities identified since 2021